loading page

Efficacy of Hyper-CVAD drug regimen in Adult T-Cell leukemia Patients: A Randomized Clinical Trial.
  • +5
  • Mostafa Kamandi,
  • Fereshteh Moghaddamnia,
  • Sajad Ataei Azimi,
  • Abolghasem Allahyari,
  • Hossein Rahimi,
  • Mohsen Seddigh Shamsi,
  • Mohammad Moeini Nodeh,
  • Mohammad Taghi Shakeri
Mostafa Kamandi
Mashhad University of Medical Sciences Faculty of Medicine

Corresponding Author:[email protected]

Author Profile
Fereshteh Moghaddamnia
Mashhad University of Medical Sciences Faculty of Medicine
Author Profile
Sajad Ataei Azimi
Mashhad University of Medical Sciences Faculty of Medicine
Author Profile
Abolghasem Allahyari
Mashhad University of Medical Sciences Faculty of Medicine
Author Profile
Hossein Rahimi
Mashhad University of Medical Sciences Faculty of Medicine
Author Profile
Mohsen Seddigh Shamsi
Mashhad University of Medical Sciences Faculty of Medicine
Author Profile
Mohammad Moeini Nodeh
Mashhad University of Medical Sciences Faculty of Medicine
Author Profile
Mohammad Taghi Shakeri
Mashhad University of Medical Sciences Department of Biostatistics
Author Profile

Abstract

Background: Adult T-cell leukemia (ATL) is one of the most important hematological malignancies caused by the HTLV-I virus. The disease has a poor prognosis due to the low median survival of the patients. Aim: Given the need for effective therapeutic interventions, this study aimed to investigate the efficacy of Hyper-CVAD and As/IFN/AZT regimens and compare their performance. Methods and Results: This study is a randomized clinical trial conducted on individuals recently diagnosed with acute ATL. Individuals who tested positive in a HTLV-I serological test based on ELISA and/or PCR were randomly assigned to receive treatment with either Hyper-CVAD or As/IFN/AZT using block randomization. The drug regimens were administered for 60 days, and patients underwent follow-up assessments. Overall, 29 individuals were enrolled in the trial. No significant differences were found in gender distribution, LDH levels, and lymphocyte counts between the two groups (P-value>0.05). The treatment response rates for the Hyper-CVAD and As/IFN/AZT regimens were 46.67% and 35.71%, respectively, with no significant differences between the two groups (P-value >0.05). Survival analysis revealed a significant difference in survival between the two groups, favoring those under the Hyper-CVAD regimen (P-value<0.05). The predominant toxicities were hematological toxicities; one patient in the Hyper-CVAD group experienced Grade 3 toxicity, while three patients in the As/IFN/AZT group experienced Grade 3 toxicity. Conclusion: The results of this study suggest no significant differences in efficacy between the Hyper-CVAD and As/IFN/AZT regimens. Additionally, higher toxicity rates were observed in the As/IFN/AZT regimen. Further investigations into frontline treatments and the timing of the As/IFN/AZT regimen in future studies may provide valuable insights in this regard. Clinical Trial Registration: IRCT20210703051770N1.
11 Mar 2024Submitted to Cancer Reports
01 Apr 2024Submission Checks Completed
01 Apr 2024Assigned to Editor
17 Apr 2024Review(s) Completed, Editorial Evaluation Pending
22 Apr 2024Reviewer(s) Assigned
31 May 2024Editorial Decision: Revise Major